Open in interactive viewer → charts, metric popovers & call review

TriSalus: The Sales Force Was Doubled; The Ramp Was Misjudged

Q3 revenue grew 11%, but guidance collapsed to 2–6% as new territories lagged and a Y90 procedure shift outran the product line—until TriNav Advance.
TLSI · Earnings Call · 2026-11-10
The third quarter was supposed to be the proof point. TriSalus had spent the first half of 2026 more than doubling its commercial footprint, telling investors the new reps would drive a second-half acceleration. Instead, revenue rose 11% year over year to $12.9 million and 13% sequentially—growth, but below plan—and management cut full-year guidance to $46 million to $48 million, or 2% to 6% growth. “We are updating our full year 2026 revenue guidance to $46 million to $48 million, reflecting approximately 2% to 6% growth over full year 2025.” — David Patience, Chief Financial Officer · 2026-11-10 For a company that had been framing itself around 50% growth not long ago, that is not a wobble; it is a reset. The phrase commercial organization transition has now been the explanation for two consecutive quarters.

Two misses, one of which is fixable

Management blamed two things. First, the new expansion territories—about eight territories, roughly a third of the field—where reps had no prior TriNav relationships.

there's about 8 of them, and they're still growing month-over-month and growing sequentially. We just misjudged the ramp on those territories.

Mary Szela, President and Chief Executive Officer · 2026-11-10
That is a clean admission. The second is more interesting: a faster-than-anticipated shift toward super selective Y90 administration in small distal vessels, a technique TriNav could not fully address until the September FDA clearance of TriNav Advance. “While growth came in below our expectation, this reflects the timing of our commercial organization transition and new account ramp in addition to a faster-than-anticipated shift towards super selective Y90 administration in small distal vessels.” — Mary Szela, President and Chief Executive Officer · 2026-11-10 Dr. Marshall described the clinical logic: super selective treatment is used in very small tumors, roughly 2 centimeters and smaller, and TriNav Advance lets physicians keep their preferred microcatheter while still getting pressure-enabled delivery. The company says it can now address all of those cases; the product is in limited launch, and Q4 guidance includes no Advance revenue. The competitive frame is also unchanged: TriSalus still sells against the standard microcatheter, a decades-old commodity, and its pitch is economics plus outcomes.

The sales-force promise meets its own history

This is where the call gets uncomfortable. In March, management said it was "meaningfully doubling the size of the commercial organization" and that this would "meaningfully drive acceleration in sales at the beginning in the second half of the year and forward." “meaningfully doubling the size of the commercial organization... meaningfully drive acceleration in sales at the beginning in the second half of the year and forward.” — Mary Szela, President and Chief Executive Officer · 2026-03-05 In May, after Q1 disruption, Mary said the new reps had a 6- to 9-month ramp and that "we anticipate for the remainder of the year just to see month-over-month continual growth." “We see a 6- to 9-month ramp. All the reps are largely in place. So we are we anticipate for the remainder of the year just to see month-over-month continual growth.” — Mary T. Szela, President and Chief Executive Officer · 2026-05-12 Three months later, the ramp is still the problem. The new reps are only four to six months in, so the calendar can still rescue the thesis—but the burden of proof has shifted. The stock has already voted: the tape shows a 26.6% decline over the last 90 days and a 39.4% drawdown from the August peak, leaving a roughly $198 million market cap. The market is no longer paying for the promise; it is waiting for the productivity.

Reimbursement is the real 2027 call option

The most tangible positive in the quarter was not the top line. It was CMS. The 2027 OPPS final rule reassigns C8004, the Y90 mapping angiogram, from APC-5193 to APC 5194, lifting national Medicare payment from about $11,874 to about $20,910—a 76% increase effective January 1, 2027. C9797, the PEDD embolization code, stays in APC-5194 and rises from about $18,729 to about $20,910. And G0577, the new code for PEDD in the office based lab setting, gets national pricing of about $13,788 per procedure, up from about $12,300 in the proposed rule. “Taken together, these decisions give PEDD a payment path in every site of care, including hospital outpatient, ambulatory surgery center and office-based lab heading into our 2027 OBL launch.” — Mary Szela, President and Chief Executive Officer · 2026-11-10 That is a genuine company-specific catalyst, and it sits on a broader site of service wave—the global tape has recently bid up a basket of site-of-service names. If OBL migration continues, TriSalus gets a second growth engine without needing to win every hospital capital cycle.

The numbers underneath the story

The financial shape is not broken. Gross margin was 86% in Q3 versus 84% a year ago, and the trailing figure sits at 86.8%. R&D fell to $3.2 million from $5.7 million as the nelitolimod trial costs rolled off, and adjusted EBITDA loss narrowed to $4.7 million from $5.4 million. The company ended the quarter with $41 million in cash and says it fully funds the plan. But the valuation still assumes a recovery: at 6.2x revenue, TriSalus is not cheap for a 2% to 6% growth year. The bull case requires 2027 to look like the original thesis: a full year of expanded sales productivity, TriNav Advance, and the reimbursement tailwind all landing together. The bear case is simpler: the company has now missed its own sales-force ramp once, and the fix is another launch and another "wait for next year." The honest read is that Q3 changed the timing, not necessarily the destination. The liver embolization market is large, the clinical evidence program is real—11 studies, 27 sites, more than 400 patients—and the reimbursement win is concrete. But until the new territories produce, TriSalus is a show-me story with a 2027 catalyst list and a stock that has already stopped giving management the benefit of the doubt.